Concepts (89)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Agents, Immunological | 2 | 2020 | 50 | 1.190 |
Why?
|
| Central Nervous System Infections | 1 | 2021 | 9 | 0.700 |
Why?
|
| Autoimmune Diseases of the Nervous System | 1 | 2021 | 13 | 0.670 |
Why?
|
| Paraneoplastic Syndromes, Nervous System | 1 | 2020 | 2 | 0.630 |
Why?
|
| ELAV Proteins | 1 | 2020 | 2 | 0.630 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2021 | 105 | 0.630 |
Why?
|
| Antibodies, Antinuclear | 1 | 2020 | 41 | 0.610 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2020 | 64 | 0.610 |
Why?
|
| Liver Transplantation | 1 | 2021 | 220 | 0.590 |
Why?
|
| Autoantigens | 1 | 2020 | 139 | 0.580 |
Why?
|
| Nervous System Diseases | 1 | 2020 | 108 | 0.560 |
Why?
|
| Neurocysticercosis | 1 | 2018 | 1 | 0.560 |
Why?
|
| Tegmentum Mesencephali | 1 | 2017 | 7 | 0.530 |
Why?
|
| Blepharoptosis | 1 | 2017 | 7 | 0.530 |
Why?
|
| Ophthalmoplegia | 1 | 2017 | 4 | 0.530 |
Why?
|
| Basilar Artery | 1 | 2017 | 34 | 0.520 |
Why?
|
| Receptors, Cholinergic | 1 | 2017 | 24 | 0.510 |
Why?
|
| Myasthenia Gravis | 1 | 2017 | 12 | 0.510 |
Why?
|
| Cerebral Infarction | 1 | 2017 | 85 | 0.500 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2017 | 61 | 0.500 |
Why?
|
| Immunoglobulin G | 1 | 2017 | 465 | 0.440 |
Why?
|
| Neoplasms | 1 | 2020 | 1367 | 0.300 |
Why?
|
| Immunologic Factors | 2 | 2021 | 110 | 0.280 |
Why?
|
| Disease Progression | 3 | 2020 | 1219 | 0.230 |
Why?
|
| Middle Aged | 7 | 2021 | 18254 | 0.200 |
Why?
|
| Humans | 11 | 2021 | 65095 | 0.180 |
Why?
|
| Demyelinating Autoimmune Diseases, CNS | 1 | 2021 | 1 | 0.180 |
Why?
|
| Living Donors | 1 | 2021 | 79 | 0.170 |
Why?
|
| Emergencies | 1 | 2021 | 123 | 0.160 |
Why?
|
| Disease Management | 2 | 2020 | 235 | 0.160 |
Why?
|
| Antibodies, Neoplasm | 1 | 2020 | 27 | 0.160 |
Why?
|
| Etoposide | 1 | 2020 | 34 | 0.160 |
Why?
|
| Cerebellar Neoplasms | 1 | 2020 | 11 | 0.160 |
Why?
|
| Carcinoma, Small Cell | 1 | 2020 | 23 | 0.160 |
Why?
|
| Carboplatin | 1 | 2020 | 47 | 0.160 |
Why?
|
| Immunomodulation | 1 | 2020 | 30 | 0.160 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2020 | 59 | 0.160 |
Why?
|
| Herpesvirus 4, Human | 1 | 2021 | 199 | 0.150 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 169 | 0.150 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 372 | 0.150 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 298 | 0.140 |
Why?
|
| Registries | 1 | 2021 | 913 | 0.130 |
Why?
|
| Rituximab | 1 | 2017 | 89 | 0.120 |
Why?
|
| Neuroimaging | 1 | 2018 | 164 | 0.120 |
Why?
|
| Female | 6 | 2021 | 33997 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 464 | 0.120 |
Why?
|
| Brain | 2 | 2015 | 1603 | 0.120 |
Why?
|
| Tropical Medicine | 1 | 2015 | 2 | 0.110 |
Why?
|
| Peripheral Nervous System | 1 | 2015 | 12 | 0.110 |
Why?
|
| Neglected Diseases | 1 | 2015 | 12 | 0.110 |
Why?
|
| Brain Diseases | 1 | 2016 | 76 | 0.110 |
Why?
|
| Thrombectomy | 1 | 2017 | 254 | 0.110 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2014 | 10 | 0.110 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2014 | 13 | 0.100 |
Why?
|
| Hospitalization | 1 | 2021 | 1392 | 0.100 |
Why?
|
| Oligopeptides | 1 | 2014 | 135 | 0.100 |
Why?
|
| Spinal Cord | 1 | 2015 | 209 | 0.100 |
Why?
|
| Secondary Prevention | 1 | 2014 | 165 | 0.100 |
Why?
|
| Seizures | 1 | 2014 | 141 | 0.100 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 704 | 0.100 |
Why?
|
| Male | 4 | 2021 | 31014 | 0.090 |
Why?
|
| Retrospective Studies | 2 | 2021 | 6859 | 0.080 |
Why?
|
| Biomarkers, Tumor | 1 | 2014 | 524 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 801 | 0.080 |
Why?
|
| Treatment Outcome | 1 | 2020 | 5784 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 644 | 0.070 |
Why?
|
| Multiple Myeloma | 1 | 2014 | 369 | 0.070 |
Why?
|
| Aged | 1 | 2021 | 14945 | 0.060 |
Why?
|
| New England | 1 | 2021 | 271 | 0.040 |
Why?
|
| Mortality | 1 | 2021 | 161 | 0.040 |
Why?
|
| Comorbidity | 1 | 2021 | 1119 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2021 | 1015 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 1559 | 0.030 |
Why?
|
| Metronidazole | 1 | 2016 | 10 | 0.030 |
Why?
|
| Cephalosporins | 1 | 2016 | 21 | 0.030 |
Why?
|
| Penicillins | 1 | 2016 | 32 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2021 | 2618 | 0.030 |
Why?
|
| Nimodipine | 1 | 2014 | 3 | 0.030 |
Why?
|
| Piracetam | 1 | 2014 | 9 | 0.030 |
Why?
|
| Nootropic Agents | 1 | 2014 | 14 | 0.030 |
Why?
|
| Polyneuropathies | 1 | 2014 | 13 | 0.030 |
Why?
|
| Neurologic Examination | 1 | 2014 | 54 | 0.030 |
Why?
|
| Bortezomib | 1 | 2014 | 59 | 0.030 |
Why?
|
| Anticonvulsants | 1 | 2014 | 104 | 0.020 |
Why?
|
| Antihypertensive Agents | 1 | 2014 | 179 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2015 | 460 | 0.020 |
Why?
|
| Risk Factors | 1 | 2021 | 5422 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 2245 | 0.010 |
Why?
|
| Adult | 1 | 2021 | 17351 | 0.010 |
Why?
|